Premier Perspectives The blog for insider insights in clinical development Consulting Optimized 505(b)(1) and 505(b)(2) Clinical Pharmacology Programs to Accelerate Drug Development By Jayesh Patel August 12, 2024 × ALSO OF INTERESTKey Considerations When Designing a Phase 1...Nostalgia or Shell Shock? Assessing PTSD Is a...Gene Therapy 101: From the 1960s to Today
